AbbVie Inc.ABBVNYSE
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +5.60% | +8.39% | +6.65% | +9.10% | +10.04% |
| Gross Profit Growth | +24.53% | +13.69% | +7.96% | +2.19% | +30.41% |
| EBITDA Growth | -86.11% | -1.98% | -13.17% | -28.00% | +2896.95% |
| Operating Income Growth | -146.64% | +33.42% | +22.41% | -50.30% | +0.00% |
| Net Income Growth | -102.68% | -6.06% | -31.53% | -88.08% | +0.00% |
| EPS Growth | -103.93% | -6.49% | -31.17% | -88.69% | +0.00% |
| EPS Diluted Growth | -103.93% | -6.49% | -31.17% | -88.72% | +0.00% |
| Weighted Average Shares Growth | +0.17% | -0.06% | +0.17% | +0.17% | +0.64% |
| Weighted Average Shares Diluted Growth | +0.06% | -0.06% | +0.06% | +0.00% | +0.06% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +48.29% | -59.53% | +126.90% | +28.95% | -25.96% |
| Free Cash Flow Growth | +48.57% | -63.61% | +140.59% | +44.82% | -27.65% |
| Receivables Growth | -2.12% | +4.42% | +7.79% | +11.31% | +15.29% |
| Inventory Growth | +2.00% | +6.62% | +17.59% | +10.97% | +18.42% |
| Asset Growth | +0.33% | -8.54% | -3.35% | -6.64% | -0.89% |
| Book Value per Share Growth | -67.96% | -82.26% | +0.00% | +0.00% | +0.00% |
| Debt Growth | +12.84% | -5.56% | -0.22% | -3.29% | +1.52% |
| R&D Expense Growth | +206.65% | +6.60% | +9.39% | +8.87% | -61.93% |
| SG&A Expenses Growth | +20.73% | -0.66% | -3.67% | -15.12% | +1.04% |